We developed a gene therapy approach for CMT1X using an AAV9 vector to deliver the GJB1/Cx32 gene under the myelin protein zero (Mpz) promoter for targeted expression in Schwann cells. This evidence concerns the gene MPZ and X-linked Charcot-Marie-Tooth disease type 1.